JP7260477B2 - Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 - Google Patents

Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 Download PDF

Info

Publication number
JP7260477B2
JP7260477B2 JP2019546149A JP2019546149A JP7260477B2 JP 7260477 B2 JP7260477 B2 JP 7260477B2 JP 2019546149 A JP2019546149 A JP 2019546149A JP 2019546149 A JP2019546149 A JP 2019546149A JP 7260477 B2 JP7260477 B2 JP 7260477B2
Authority
JP
Japan
Prior art keywords
chimeric protein
domain
protein
type
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019546149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508068A (ja
JP2020508068A5 (https=
Inventor
シュレイバー，テイラー
フロム，ジョージ
シルヴァ，スレシュ デ
Original Assignee
シャタック ラボ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャタック ラボ，インコーポレイテッド filed Critical シャタック ラボ，インコーポレイテッド
Publication of JP2020508068A publication Critical patent/JP2020508068A/ja
Publication of JP2020508068A5 publication Critical patent/JP2020508068A5/ja
Priority to JP2023062366A priority Critical patent/JP7620045B2/ja
Application granted granted Critical
Publication of JP7260477B2 publication Critical patent/JP7260477B2/ja
Priority to JP2025003769A priority patent/JP2025061180A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019546149A 2017-02-27 2018-02-27 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 Active JP7260477B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023062366A JP7620045B2 (ja) 2017-02-27 2023-04-06 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP2025003769A JP2025061180A (ja) 2017-02-27 2025-01-09 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762464002P 2017-02-27 2017-02-27
US62/464,002 2017-02-27
PCT/US2018/020037 WO2018157162A1 (en) 2017-02-27 2018-02-27 Tigit- and light-based chimeric proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023062366A Division JP7620045B2 (ja) 2017-02-27 2023-04-06 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質

Publications (3)

Publication Number Publication Date
JP2020508068A JP2020508068A (ja) 2020-03-19
JP2020508068A5 JP2020508068A5 (https=) 2021-04-08
JP7260477B2 true JP7260477B2 (ja) 2023-04-18

Family

ID=63253416

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019546149A Active JP7260477B2 (ja) 2017-02-27 2018-02-27 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP2019546144A Active JP7128195B2 (ja) 2017-02-27 2018-02-27 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
JP2022130749A Pending JP2022159510A (ja) 2017-02-27 2022-08-18 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
JP2023062366A Active JP7620045B2 (ja) 2017-02-27 2023-04-06 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP2025003769A Withdrawn JP2025061180A (ja) 2017-02-27 2025-01-09 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019546144A Active JP7128195B2 (ja) 2017-02-27 2018-02-27 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
JP2022130749A Pending JP2022159510A (ja) 2017-02-27 2022-08-18 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
JP2023062366A Active JP7620045B2 (ja) 2017-02-27 2023-04-06 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP2025003769A Withdrawn JP2025061180A (ja) 2017-02-27 2025-01-09 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質

Country Status (15)

Country Link
US (8) US20190367579A1 (https=)
EP (2) EP3585425A4 (https=)
JP (5) JP7260477B2 (https=)
KR (1) KR102745835B1 (https=)
CN (3) CN118994414A (https=)
AU (2) AU2018223821B2 (https=)
BR (1) BR112019017298A2 (https=)
CA (2) CA3054127A1 (https=)
IL (2) IL313003A (https=)
MX (1) MX2019009812A (https=)
MY (1) MY207687A (https=)
PH (1) PH12019501533A1 (https=)
SG (1) SG11201906465YA (https=)
WO (2) WO2018157162A1 (https=)
ZA (1) ZA201905488B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019009812A (es) 2017-02-27 2019-10-14 Shattuck Labs Inc Proteinas quimericas basadas en tigit y light.
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
KR20210025054A (ko) * 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 이형이량체 단백질 및 이의 용도
AU2019328305A1 (en) * 2018-08-29 2021-03-04 Shattuck Labs, Inc. Combination therapies comprising tim-3-based chimeric proteins
JP2022512539A (ja) * 2018-08-29 2022-02-07 シャタック ラボ，インコーポレイテッド 併用療法
WO2020047319A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising sirp alpha-based chimeric proteins
EP3844280A4 (en) * 2018-08-31 2022-09-14 Yale University ENPP1 POLYPEPTIDES AND METHODS OF USE
WO2020051248A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
CA3120715A1 (en) 2018-11-21 2020-05-28 Mayo Foundation For Medical Education And Research Adenoviruses and methods for using adenoviruses
US20220185863A1 (en) * 2019-02-28 2022-06-16 Shattuck Labs, Inc. Combination therapies
IL292788B2 (en) * 2019-04-29 2023-12-01 Mayo Found Medical Education & Res Multivalent pd-l1 binding compounds for treating cancer
CN112111437B (zh) * 2020-05-25 2023-09-05 江南大学 2’-岩藻糖基乳糖产量提高的重组枯草芽孢杆菌及其构建方法
BR112022024221A2 (pt) * 2020-06-02 2022-12-20 Arcus Biosciences Inc Anticorpos para tigit
CN115916348A (zh) 2020-06-18 2023-04-04 基因泰克公司 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
CN111808800B (zh) * 2020-07-20 2022-08-26 中南大学湘雅二医院 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用
MX2023003142A (es) * 2020-09-17 2023-05-17 Shattuck Labs Inc Dosificacion clinica de proteina quimerica sirp1a.
EP4237000A4 (en) * 2020-11-02 2024-09-18 Athae Bio, Inc. TWO-DOMAIN MULTIMERIC FUSION PROTEINS
EP4255464A4 (en) * 2020-12-03 2025-02-26 Shattuck Labs, Inc. METHODS OF TREATING CANCER USING CHIMERIC PROTEINS FORMED FROM TIGIT AND LIGHT
CN116897202A (zh) * 2021-02-24 2023-10-17 科济生物医药（上海）有限公司 Tigit工程化细胞及其组合物
CN115260312B (zh) * 2021-04-30 2025-02-14 保诺科技（北京）有限公司 结合ox40的抗体或抗原结合片段
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
CN115960247A (zh) * 2021-10-13 2023-04-14 苏州科锐迈德生物医药科技有限公司 基于t7rna聚合酶的融合多肽及其制备方法、用途
CA3236824A1 (en) * 2021-11-01 2023-05-04 Taylor Schreiber Modified mrna therapeutics
CN114209815B (zh) * 2021-11-22 2024-04-26 山东大学 一种药物组合物及其制备方法和应用
WO2023105281A1 (en) * 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
CN114196691B (zh) * 2021-12-28 2023-08-11 重庆澳龙生物制品有限公司 一种制备防治牛、羊棘球蚴病多表位重组疫苗的基因、蛋白质、疫苗和应用
EP4537107A2 (en) 2022-06-07 2025-04-16 Genentech, Inc. Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
CN117624375A (zh) * 2022-08-30 2024-03-01 北京卡替医疗技术有限公司 增强受体、表达增强受体的免疫细胞及其用途
CN116350748A (zh) * 2022-11-01 2023-06-30 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Tigit融合蛋白在制备用于治疗系统性红斑狼疮药物中的应用
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN116041542B (zh) * 2022-12-06 2026-02-17 上海恩凯细胞技术有限公司 逆转肿瘤微环境抑制性信号的nk细胞制备方法及应用
CN116037072B (zh) * 2023-02-24 2025-01-03 宁夏医科大学 一种血清抗体亲和分离材料的制备方法与应用
CN116925236B (zh) * 2023-05-12 2024-06-04 上海恩凯细胞技术有限公司 嵌合转换受体及其应用
WO2024260419A1 (en) * 2023-06-22 2024-12-26 Fbd Biologics Limited Multi-targeting protein complex and methods of use thereof
CN116982600B (zh) * 2023-09-14 2025-11-18 江苏集萃药康生物科技股份有限公司 一种cd69人源化小鼠模型的构建方法及其应用
CN119930791A (zh) * 2023-11-02 2025-05-06 重庆精准生物技术有限公司 特异性tigit肽段
WO2025140345A1 (zh) * 2023-12-29 2025-07-03 沈阳三生制药有限责任公司 一种tigit多肽及tigit/ctla4融合蛋白

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013000234A1 (en) 2011-06-28 2013-01-03 Huabo Biopharm Co., Ltd A novel recomnimant bifunctional fusion protein and its preparation and use
JP2018529363A (ja) 2015-10-01 2018-10-11 ヒート バイオロジクス，インコーポレイテッド Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
AU661360B2 (en) 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
WO2001049318A1 (en) 2000-01-03 2001-07-12 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
US20110041190A1 (en) 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
US7696168B2 (en) * 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
MXPA06003686A (es) 2003-10-03 2007-03-01 Brigham & Womens Hospital Ligandos tim-3 y sus metodos.
ATE555133T1 (de) 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
AU2007249709A1 (en) 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. CD47 related compositions and methods for treating immunological diseases and disorders
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
WO2007149880A2 (en) 2006-06-21 2007-12-27 Genentech, Inc. Crystal structure of ox40l and ox40l complexed with ox40 receptor
WO2008061377A1 (en) 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
US8263081B2 (en) 2007-05-14 2012-09-11 The University Of Chicago Antibody-light fusion products for cancer therapeutics
AU2009205665B2 (en) 2008-01-15 2013-12-05 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
WO2009114110A1 (en) 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
SG191698A1 (en) 2008-06-30 2013-07-31 Univ Pennsylvania Fn14/trail fusion proteins
NZ590667A (en) 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
DK2604693T3 (en) 2008-07-21 2016-05-30 Apogenix Gmbh Single-chain TNFSF molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
US20110237498A1 (en) * 2008-12-19 2011-09-29 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
CA2755198A1 (en) 2009-03-13 2010-09-16 Mark L. Tykocinski Ox40/trail fusion proteins
CA3083324A1 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
CN103261217B (zh) 2010-11-11 2017-04-26 港大科桥有限公司 可溶性 pd‑1变体、融合构建体及其用途
RS55609B1 (sr) 2011-04-13 2017-06-30 Bristol Myers Squibb Co Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
US10179164B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
EP3549611B1 (en) 2011-07-29 2021-06-30 The Trustees of the University of Pennsylvania Switch costimulatory receptors
AU2012369202A1 (en) 2012-02-06 2014-09-25 Providence Health & Services - Oregon Cancer treatment and monitoring methods using OX40 agonists
CN110563850A (zh) 2012-04-30 2019-12-13 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
US9745381B2 (en) 2012-05-18 2017-08-29 Scott & White Healthcare (Swh) Bispecific scFv immunofusion (BIf)
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
ES2914814T3 (es) 2012-12-17 2022-06-16 Pf Argentum Ip Holdings Llc Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
WO2014106839A1 (en) 2013-01-01 2014-07-10 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
EP2950814A4 (en) 2013-01-31 2016-06-08 Univ Jefferson FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
US10533054B2 (en) 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
PT2961831T (pt) 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
CA3081073C (en) 2013-03-12 2023-09-12 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
EP3094650A2 (en) 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
CN106170498A (zh) 2014-01-14 2016-11-30 科马布有限公司 抗‑light抗体
WO2015112534A2 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
KR102314088B1 (ko) 2014-03-24 2021-10-15 이뮨원코 바이오파마슈티컬즈 (상하이) 컴퍼니 리미티드 새로운 이중 기능성의 재조합 융합 단백질, 이의 제조 방법 및 용도
RU2016150096A (ru) 2014-05-29 2018-07-02 МЕДИММЬЮН, ЭлЭлСи Белки слияния на основе ox40l и пути их применения
EP3160497A4 (en) 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
TWI759810B (zh) 2014-08-08 2022-04-01 美商Ａｌｘ腫瘤技術股份有限公司 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
HUE046661T2 (hu) 2014-08-15 2020-03-30 Merck Patent Gmbh SIRP-alfa immunglobulin fúziós proteinek
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
WO2016112983A1 (en) * 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
US11161907B2 (en) * 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
BR112017016681A2 (pt) 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
CA2994935A1 (en) 2015-05-18 2016-11-24 Ab Initio Biotherapeutics, Inc. Sirp polypeptide compositions and methods of use
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
MX2019009812A (es) * 2017-02-27 2019-10-14 Shattuck Labs Inc Proteinas quimericas basadas en tigit y light.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013000234A1 (en) 2011-06-28 2013-01-03 Huabo Biopharm Co., Ltd A novel recomnimant bifunctional fusion protein and its preparation and use
JP2018529363A (ja) 2015-10-01 2018-10-11 ヒート バイオロジクス，インコーポレイテッド Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法

Also Published As

Publication number Publication date
WO2018157165A1 (en) 2018-08-30
KR102745835B1 (ko) 2024-12-24
AU2022218575A1 (en) 2022-11-10
CN110381983A (zh) 2019-10-25
CN110381983B (zh) 2024-07-09
PH12019501533A1 (en) 2020-02-24
IL268198A (en) 2019-09-26
US20220227831A1 (en) 2022-07-21
KR20190122667A (ko) 2019-10-30
US20200283496A1 (en) 2020-09-10
BR112019017298A2 (pt) 2020-04-14
IL268198B2 (en) 2024-10-01
AU2018223821A1 (en) 2019-07-11
ZA201905488B (en) 2024-02-28
JP7620045B2 (ja) 2025-01-22
US20240190939A1 (en) 2024-06-13
MY207687A (en) 2025-03-12
CN110234345A (zh) 2019-09-13
US11332509B2 (en) 2022-05-17
EP3585425A4 (en) 2020-10-28
US20220315637A1 (en) 2022-10-06
JP2022159510A (ja) 2022-10-17
JP2020508068A (ja) 2020-03-19
CN118994414A (zh) 2024-11-22
IL313003A (en) 2024-07-01
EP3585425A1 (en) 2020-01-01
EP3585418A4 (en) 2020-11-25
SG11201906465YA (en) 2019-08-27
IL268198B1 (en) 2024-06-01
US20200222503A1 (en) 2020-07-16
RU2019125682A3 (https=) 2021-12-03
JP2020508329A (ja) 2020-03-19
US20200399342A1 (en) 2020-12-24
US10899817B2 (en) 2021-01-26
WO2018157162A1 (en) 2018-08-30
CA3054127A1 (en) 2018-08-30
US10927159B2 (en) 2021-02-23
JP2023076695A (ja) 2023-06-01
EP3585418A1 (en) 2020-01-01
JP7128195B2 (ja) 2022-08-30
RU2019125682A (ru) 2021-03-29
US20190367579A1 (en) 2019-12-05
US12071465B2 (en) 2024-08-27
US20240368242A1 (en) 2024-11-07
AU2018223821B2 (en) 2022-05-19
MX2019009812A (es) 2019-10-14
JP2025061180A (ja) 2025-04-10
CA3054133A1 (en) 2018-03-30

Similar Documents

Publication Publication Date Title
JP7620045B2 (ja) Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
CN108350055B (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
JP7121029B2 (ja) Ｃｓｆ１ｒベースのキメラタンパク質
JP2023071979A (ja) Ｖｓｉｇ８ベースのキメラタンパク質
RU2775490C2 (ru) Химерные белки на основе tigit и light
HK40101388A (en) Vsig8-based chimeric proteins
HK40019689A (en) Vsig8-based chimeric proteins
HK40019689B (en) Vsig8-based chimeric proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191024

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191129

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230406

R150 Certificate of patent or registration of utility model

Ref document number: 7260477

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250